Olanzapine-induced hepatopathy in albino rats: A newer model for screening putative hepatoprotective agents, namely silymarin

被引：3

作者：

Sengupta, Parama ^{[1
]}

Bagchi, Chiranjib ^{[1
]}

Sharma, Abhishek ^{[1
]}

Majumdar, G. ^{[1
]}

Dutta, C. ^{[1
]}

Tripathi, Santanu ^{[1
]}

机构：

[1] Burdwan Med Coll & Hosp, Dept Pharmacol, Burdwan, W Bengal, India

来源：

INDIAN JOURNAL OF PHARMACOLOGY | 2010年 / 42卷 / 06期

关键词：

Olanzapine; hepatopathy; silymarin; HEPATOTOXICITY;

D O I：

10.4103/0253-7613.71924

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Backgrounds: This study was conducted to establish olanzapine-induced hepatopathy in Wistar albino rats as a newer model to screen putative hepatoprotective agents namely silymarin. Materials and Methods: Albino rats were divided into three groups, namely vehicle control group (CG), olanzapine-treated group (OZ), and olanzapine plus silymarin (OZS) treated groups. Both the OZ and OZS groups were treated with the same dose of intraperitoneal olanzapine for 6 weeks and group OZS additionally received oral silymarin. Baseline and terminal hepatic enzymes (SGOT, SGPT, and ALP) were measured in all three groups. Results: Histopathological examination of livers of both OZ and OZS groups showed degenerative changes, whereas those of control group showed normal architecture. Liver enzyme levels showed statistically significant rise in comparison to the control group as well as the respective base line values in both the test groups, but the differences in the rise of liver enzymes between the two test groups were not statistically significant. Conclusion: Olanzapine-induced hepatopathy in rats can be used as a model for screening putative hepatoprotective agents and in our setting silymarin has failed to provide any hepatoprotection.

引用

页码：376 / 379

页数：4

共 7 条

[1] A review of liver function tests during treatment with atypical antipsychotic drugs: A chart review study [J].

Atasoy, Nuray ;

Erdogan, Ayten ;

Yalug, Irem ;

Ozturk, Ulkem ;

Konuk, Numan ;

Atik, Levent ;

Ustundag, Yucel .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (06) :1255-1260

[2]

Lui S. Y., 2009, Hong Kong Medical Journal, V15, P394

[3] A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects [J].

Mitchell, Malcolm ;

Riesenberg, Robert ;

Bari, Mohammad A. ;

Marquez, Eva ;

Kurtz, Darcie ;

Falk, Deborah ;

Hardy, Thomas ;

Taylor, Cindy C. ;

Mitchell, Colin P. ;

Cavazzoni, Patrizia .

CLINICAL THERAPEUTICS, 2006, 28 (06) :881-892

[4] Long-term Treatments with Low- and High-dose Olanzapine Change Hepatocyte Numbers in Rats. A Stereological and Histopathological Study [J].

Odaci, Ersan ;

Bilen, Habip ;

Hacimuftuoglu, Ahmet ;

Keles, Osman Nuri ;

Can, Ismail ;

Bilici, Mehmet .

ARCHIVES OF MEDICAL RESEARCH, 2009, 40 (03) :139-145

[5] Severe liver enzyme elevations after three years of olanzapine treatment: A case report and review of olanzapine associated hepatotoxicity [J].

Ozcanli, Tuba ;

Erdogan, Ayten ;

Ozdemir, Samuray ;

Onen, Baris ;

Ozmen, Mine ;

Doksat, Kerem ;

Sonsuz, Abdullah .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (06) :1163-1166

[6]

Pradhan SC, 2006, INDIAN J MED RES, V124, P491

[7] Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats [J].

Tsai, J. H. ;

Liu, J. Y. ;

Wu, T. T. ;

Ho, P. C. ;

Huang, C. Y. ;

Shyu, J. C. ;

Hsieh, Y. S. ;

Tsai, C. C. ;

Liu, Y. C. .

JOURNAL OF VIRAL HEPATITIS, 2008, 15 (07) :508-514

← 1 →